

## Original Article

**Running Title:** Pulmonary Complications of Cancer Treatment in Breast Cancer Patients

Received: October 26, 2020; Accepted: October 10, 2021

### Investigation of Pulmonary Complications Induced by Radiotherapy and Chemotherapy in Patients with Breast Cancer through Spirometry, CT Scan Imaging Patterns, and Clinical Criteria in a Six-Month Follow-Up

Maryam Bahador<sup>\*</sup>, MD, Mohamad Hasan Larizadeh<sup>\*</sup>, MD, Mitra Samareh Fekri<sup>\*\*</sup>, MD, Ahmad Naghibzadeh-Tahami<sup>\*\*\*</sup>, PhD, Mina Mohseni<sup>\*\*\*\*</sup>, MD, Fateme Arabnejad<sup>\*♦</sup>, MD

<sup>\*</sup>Department Of Radiation Oncology, Kerman University of Medical Sciences, Kerman, Iran

<sup>\*\*</sup>Cardiovascular Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran

<sup>\*\*\*</sup>Modeling in Health Research Center, Institute for Future Studies in Health, Kerman University of Medical Sciences, Kerman, Iran

<sup>\*\*\*\*</sup>Department of Psychiatry, Sirjan University of Medical Sciences, Kerman, Iran

#### ♦Corresponding Author

Fateme Arabnejad, MD

Department Of Radiation Oncology,

Kerman University of Medical Sciences, Kerman, Iran

Tel: +989134414305

Email: [fateme.arabnejad@gmail.com](mailto:fateme.arabnejad@gmail.com)

#### Abstract

**Background:** The aim of this study was to determine pulmonary complications induced by radiotherapy and chemotherapy in patients with breast cancer in a six-month follow-up.

**Method:** 80 patients with breast cancer who were referred to the Radio-oncology Center in Kerman were included in the current cohort study.

At the baseline, spirometry and lung scan were obtained and all the patients were asked about their respiratory symptoms. After designing the patient's treatment, dose volume histogram data was extracted. All the tests were repeated six months after radiotherapy. The prevalence of pneumonitis and fibrosis in radiographs were determined clinically and the reduction in the values of pulmonary function test parameters was determined.

**Results:** In 40% of the patients, pulmonary volume was reduced and in 10%, pulmonary fibrosis occurred. Regarding pulmonary function before and six months after radiotherapy, the results revealed that FeV1 (l/s) parameter decreased from 2.68 to 2.48 ( $P < 0.0001$ ) six months after radiotherapy. FVC parameter also showed a decrease from 3.14 to 2.91 ( $P < 0.0001$ ) in the same span of time. The odds of developing clinical symptoms in people with pulmonary fibrosis was five times higher than of those without this condition, (OR: 5.51, 95% CI: 1.10 - 27.42), which was statistically significant ( $P = 0.03$ ). None of the factors, including mean lung dose, tamoxifen, and age, affected Fev1 and pulmonary fibrosis.

**Conclusion:** Our results indicated that 10% of the patients undergoing treatment for breast cancer developed pulmonary fibrosis and 40% of the patients suffered from reduced pulmonary volumes, which was not associated with chemotherapy regimen or the use of tamoxifen.

**Keywords:** Radiotherapy, Chemotherapy, Breast neoplasms, Complications

## Introduction

Breast cancer is the most prevalent non-skin cancer, the most common malignancy, and the second leading cause of death from cancer among women after lung cancer.<sup>1, 2</sup>

In Iranian women, breast cancer is the second most common cancer following skin cancer. Among the different types of cancer in women, 23% of cancer deaths are due to breast cancer.<sup>3, 4</sup>

Postoperative regional radiotherapy is an important factor in the treatment of breast cancer reducing regional recurrence and increasing overall patient survival. Reducing the complications of radiotherapy is important since most patients with breast cancer have a long-term survival.<sup>5</sup> Once radiotherapy is given to the chest or breast, radiation to a part of the lung is unavoidable and this accidental exposure can increase the possibility of pneumonitis and fibrosis.<sup>6</sup> The prevalence of radiation-induced pneumonitis has been reported to be 1-80% in various studies; this wide range of incidence is due to the variety of simulation techniques, treatment program, total dose, use of photons/electrons, and the use of different sample grading systems. In a recent meta-analysis of 10 different studies on the prevalence of early pulmonary complications of radiotherapy in patients with breast cancer, the overall incidence of clinical and radiological pneumonitis was reported to be 14% and 42%, respectively.<sup>5</sup> In addition to reducing the quality of life, radiation-induced pneumonitis can lead to oxygen dependence.<sup>7-9</sup>

On the other hand, chemotherapy drugs can cause pulmonary complications, such as asymptomatic radiological changes to severe respiratory problems, which is almost a common symptom. In fact, some types of pulmonary complication occur in 10-20% of all the patients receiving any type of antineoplastic drug.<sup>10</sup>

Radiation-induced pneumonitis could occur 4-12 weeks after radiotherapy. In most cases, radiation-induced pneumonitis regress spontaneously or with steroid treatment although it can also develop into radiation-induced fibrosis as a long-term complication.<sup>7</sup> Diagnosis of radiation-induced pneumonitis is based on the radiological images and non-specific clinical signs with or without changes in pulmonary function tests (PFTs). In conventional radiotherapy, if PTV lung-v20 is higher than 30% and GTV lung-v20 is higher than 33%, it is considered to be a predictive factor of symptomatic pneumonitis. An average lung dose greater than 20 Gy is also a predictor. Although the rate of lethal pneumonitis is low, it is seen in large daily fractions.<sup>12</sup> Considering the importance and prevalence of radiation-induced pneumonitis, the objective of this research was to evaluate the pulmonary complications of radiotherapy and chemotherapy in patients with breast cancer via imaging, spirometry, and clinical models.

## Methods

This work was performed as a prospective cohort study. The study population consisted of patients with breast cancer who referred to the Radio-oncology Medical Center of Afzalipour Hospital in Kerman. The present study was approved by the ethics committee of Kerman University of Medical Sciences (Ethics code: 97000427).

In this cohort work, 80 patients with breast cancer referring to the Radio-oncology Center of Afzalipour Hospital were included from the beginning of treatment after being given comprehensive information about the study and obtained informed consents. Patients with a history of asthma, previous radiotherapy, metastasis, smoking, metastasis during follow-up, or death during follow-up were excluded from the study. Before radiotherapy, a questionnaire

comprising demographic characteristics, history of chemotherapy, the affected breast side, family history, comorbidities, and patient's height and weight was completed. Information about the stage of the disease, type of surgery, the number of chemotherapy sessions and drugs, progesterone and estrogen receptors, HER2, and histological data were extracted from the patient's medical record. We performed basic spirometry for the patients and a respiratory symptoms questionnaire was completed. After designing the specific treatment for the patients, several variables, including volume of the lung receiving 20 Gy or more (V20), dose determined for the treatment of the patient (DOSE), mean lung dose, dose volume histogram, number of fields, and the presence or absence of boost, were extracted. Following radiotherapy, the patients were followed up for six months and computed tomography (CT) scan and spirometry were performed. In addition, a questionnaire for clinical diagnosis of pneumonitis was completed again. At the end of the follow-ups, the prevalence of pneumonitis and fibrosis in radiographs and reduced levels of PFT parameters were determined. Grading criteria for radiation pneumonitis in lung CT scan was as follows: 0 for no change; 1 for ground glass opacities without fuzziness of the subjacent pulmonary vessels; 2 for the findings which may vary from ground glass opacities, extending beyond the radiation field to consolidation; 3 for clear focal consolidation  $\pm$  elements of fibrosis; 4 for dense consolidation, cicatrization atelectasis, (traction bronchiectasis), significant pulmonary volume loss and thickening. Fibrosis is defined as figure 1. The results of spirometry before and after treatment were demonstrated as mean, median, and standard deviation. Their alterations were examined through SPSS software with paired t-test and their association with complications was

examined employing logistic or linear regression.  $P = 0.05$  was considered to be the level of significance.

## Results

Herein, 80 patients with breast cancer were assessed. The mean age of the patients was  $50.79 \pm 11.81$  years (age range: 28-72). The mean body mass index (BMI) of the subjects was  $24.49 \pm 4.23$  kg/m<sup>2</sup> (BMI range: 17.60-34 kg/m<sup>2</sup>). ACT was the frequent chemotherapy type among patients with breast cancer ( $n = 65$ , 81.3%). For more than half of patients, cancer occurred in the right breast ( $n = 48$ , 60%). HER2 and ER/PR were positive for 30% ( $n = 24$ ) and 71.2% ( $n = 57$ ), respectively. We applied chemotherapy before surgery (neoadjuvant) for more than half of patients ( $n = 43$ , 53.8%). The demographic and clinical information of patients is represented in table 1.

The results of our study revealed that pulmonary indexes significantly changed for patients after six months. FEV1 (Forced expiratory volume in one second) and FVC (Forced vital capacity) statistically decreased for the patients ( $P \leq 0.001$ ), but FEV1/FVC increased six months later ( $P \leq 0.001$ ). PaO<sub>2</sub> did not experience any significant changes during this period ( $P = 0.210$ ). Table 2 illustrates the pulmonary functions of the patients before and after the six-month follow-up.

According to bivariate logistic regression, the mean lung dose ( $P = 0.011$ ) and radiologic fibrosis ( $P = 0.032$ ) were related to develop clinical fibrosis following radiotherapy. The results showed that with each unit increased in mean lung dose, the odds of developing clinical fibrosis also increased (OR: 1.26, 95% CI: 1.03 – 1.53). Additionally, the patients with radiologic fibrosis had greater odds of developing clinical fibrosis versus the other patients (OR: 5.51, 95% CI: 1.10 – 27.42) (Table 3).

The results of multivariable logistic regression model revealed mean lung dose to be the only predicting factor of developing clinical fibrosis after six months of radiotherapy (OR: 1.26, 95% CI: 1.03 – 1.53,  $P = 0.011$ ).

Table 2 shows the results of paired t-test related to pulmonary function before and six months after radiotherapy. As shown in this table, FeV1 (l/s) decreased significantly six months after radiotherapy. Additionally, FVC also demonstrated a significant decrease during the same period of time. FeV1/FVC had a significant increase. Although a slight increase was reported for PaO2 parameter, the difference was not statistically significant.

The results of analysis indicated that the odds of developing clinical symptoms in people with pulmonary fibrosis was five times higher than of those without this condition, (OR: 5.51, 95% CI: 1.10 – 27.42), which was of statistical significance ( $P = 0.030$ ). The results also revealed that with each unit decrease in Fev1, the odds of developing clinical symptoms increased more than eight times although this relationship was not statistically significant ( $P = 0.203$ ). Regarding the type of treatment, the CMF diet increased the odds of developing clinical symptoms by 4%, (OR: 1.04, 95% CI: 0.2-5.42), compared to ACT, yet this relationship was not statistically significant ( $P = 0.904$ ). The analysis also proved that age had no effects on the clinical symptoms (OR: 1.01, 95% CI: 0.95 – 1.07). However, it was shown that with a single unit increase in the mean lung dose, the odds of incidence of decrease of FEV1 increased more than 26%, (OR: 1.26, 95% CI: 1.03 – 1.53), which was statistically significant ( $P = 0.011$ ) (Table 3).

The results of bivariate logistic regression models demonstrated that developing radiologic fibrosis following radiotherapy was related to age ( $P = 0.002$ ), FEV1 ( $P \leq$

0.001), FVC ( $P \leq 0.001$ ), FEV1/FVC ( $P = 0.041$ ), mean lung dose ( $P = 0.023$ ), clinical fibrosis ( $P = 0.030$ ), ER ( $P = 0.033$ ) and stage ( $P = 0.003$ ). Based on the finding, by increasing one unit in the age of the patients, the odds of radiologic fibrosis increased (OR: 1.06, 95% CI: 1.02 - 1.11). By increasing 1/10 unit of FEV1, FVC, and FEV1/FVC, the odds of radiologic fibrosis respectively increased greater than five times (OR: 5.06, 95 %CI: 2.57 – 9.95), three times (OR: 3.87, 95% CI: 2.23 – 6.72) and one time (OR: 1.07, 95% CI: 1.00 – 1.14). Increasing one unit in mean lung dose led to increasing the odds of radiologic fibrosis greater than one time (OR: 1.22, 95% CI: 1.02 – 1.46). The results revealed that the patients with clinical fibrosis had higher odds of radiologic fibrosis in comparison to other patients without clinical fibrosis (OR: 5.51, 95% CI: 1.10 – 27.42). In the current work, the patients with positive ER/PR had greater odds of radiologic fibrosis versus the other patients (OR: 3.14, 95% CI: 1.12 – 8.82). The patients with advanced stages also had higher odds of radiologic fibrosis versus the patients in early stages (OR: 4.71, 95% CI: 1.69 – 13.31) (Table 4). Finally, age ( $P = 0.133$ ), FVC ( $P \leq 0.001$ ), and FEV1/FVC ( $P = 0.032$ ) could predict the development of radiologic fibrosis among patients with breast cancer (Table 4).

Table 5 describes the factors predicting Fev1 changes. According to the table, mean lung dose, tamoxifen, and age predicted 3%, 0.04%, and 1% of the changes in Fev1, respectively. However, based on the  $\beta$ -coefficient and R2, none of these factors had any effects on Fev1 alternation ( $P > 0.050$ ).

## Discussion

The findings of the present study on pulmonary function before and six months after radiotherapy indicated that FeV1 (l/s) decreased significantly in half a year. FVC also revealed a significant decrease six

months after radiotherapy. Although a slight increase was reported for PaO<sub>2</sub>, this difference was not of significance. Accordingly, it was found that the reduction of pulmonary volume and pulmonary fibrosis occurred in approximately 40% and 10% of the patients, respectively. On the other hand, no decrease in the oxygen level was observed in any of the patients.

FEV is short for forced expiratory volume. FEV<sub>1</sub> is the amount of air you can force from your lungs in one second. Forced vital capacity (FVC) is the total amount of air exhaled during the FEV test. In obstructive pulmonary diseases, the ratio of FEV<sub>1</sub>/FVC decreases.

As we mentioned above, the results showed a reduction of FEV<sub>1</sub> and FVC, but no differences in the proportion of FEV<sub>1</sub>/FVC. This demonstrates the reduction of these pulmonary volumes (FEV<sub>1</sub>, FVC) without an obstructive component since there were no differences in the FEV<sub>1</sub>/FVC ratio before and after radiation.

Mehnati et al. (2020) also implied that FEV and FVC decreased three and six months after radiotherapy, which is consistent with the results of this work. However, only the decrease in FEV<sub>1</sub> was significant.<sup>13</sup> In addition, AlSaeed et al. (2017) also reported a significant decrease in FVC, FEV<sub>1</sub>, and DLCO 90 days after treatment (Baseline 2.94, 2.52, 8.04 versus after 90 days 2.68, 2.30, 7.81, respectively) while VO<sub>2</sub> max was not affected significantly. Although the findings indicated a limitation for pulmonary function, none of the patients had any symptom.<sup>14</sup> In another study by Goldman et al. (2014), the findings revealed that FEV<sub>1</sub> and TLC after radiotherapy (RT) in long-term follow-up were reduced respectively by 9% and 7% ( $P < 0.001$ ).<sup>15</sup> The findings of Abdemanafi et al. (2019) showed a decreasing trend in pulmonary parameters three months after radiotherapy and a slight improvement six months after

treatment. These changes, three and six months after treatment, did not expose the patient to lung disease and irreversible reduction of lung volume.<sup>16</sup> In a study by Hernberg et al. (2002), the prevalence of clinical symptoms was 29% and the changes in CT scan were 48%, which occurred mostly in the first three months following radiotherapy.<sup>17</sup> In a study by Giridhar et al. (2015), a relationship between radiation pneumonitis and the total lung volume, mean lung dose, volume of the lung receiving 20 Gy or more (V<sub>20</sub>), and volume of the lung receiving 30 Gy or more (V<sub>30</sub>) was reported.<sup>18</sup> In the study of Lind et al. (2002), no association was found between the clinical symptoms of radiation-induced pneumonitis and its radiological symptoms.<sup>19</sup> Accordingly, it seems that radiation-induced fibrosis and pneumonitis are usually accompanied by factors, such as irradiated lung volume, mean lung dose, fractionation, concomitant use of chemotherapy and radiotherapy, use of supraclavicular field, radiotherapy techniques, cigarette smoking, tamoxifen, age, BMI, central lung distance (CLD), and pulmonary function before radiotherapy. Inconsistent with the findings of the present work, the results of a study by Fragkandrea et al. (2013) indicated that there were no statistically significant decreases in the parameters FEV<sub>1</sub>, FVC, FEV<sub>25</sub>, FEV<sub>50</sub>, and DLCO in the two treatment groups at three and six months after RT completion.<sup>20</sup> A study by Khoshbin et al. (2011) implied that there were no differences between FEV<sub>1</sub> and FVC before and after radiotherapy. In addition, no abnormal symptoms were observed in any of the patients.<sup>21</sup> The findings of this study proved that there were no significant relationships between the reduction of respiratory volumes and chemotherapy regimen. Moreover, we observed no significant relationship between tamoxifen

consumption and respiratory volumes. However, Vasiljevic et al. (2018) reported that a combination of tamoxifen and Goserelin may increase the risk of developing pneumonitis.<sup>23</sup>

The incidence of pulmonary complications is probable as a result of radiation therapy for breast cancer; however, their severity varies according to different treatment conditions. Clinical complications of radiotherapy are divided into acute and chronic. Acute complications occur about 6-12 weeks after radiotherapy, which are reported as pneumonitis. Chronic complications occur 6-12 months following radiotherapy, which are reported as pulmonary fibrosis.<sup>24, 25</sup> Decreased pulmonary parameters after radiotherapy treatment may be due to incomplete lung expansion and as a result, air accumulation. This indicates restrictive pulmonary diseases.<sup>26</sup> This reduction in lung volume does not seem to have much effect on people's normal lives. Meanwhile, it can reduce a person's respiratory capacity during exercise or surgery, which should be considered seriously.<sup>25</sup> Several similar studies have reported chemotherapy to be a factor affecting the radiotherapy outcomes. Therefore, chemotherapy reduces diffusing capacity of the lung for carbon monoxide (DLCO),<sup>24</sup> which may lead to discrepancies in the findings.

### **Limitations**

The limitations of this study include the small sample size and the limited follow-up time. It is also recommended to utilize additional diagnostic measures, such as high resolution CT (HRCT) or DLCO to assess the pulmonary function in patients more accurately. It is suggested to examine the effect of different radiotherapy methods on pulmonary volumes.

### **Conclusion**

According to the results of this study, 10% of the patients with breast cancer undergoing radiotherapy and chemotherapy, developed pulmonary fibrosis and 40% had a reduction in lung volumes, none of which had any relationship with chemotherapy or tamoxifen consumption. Considering the problems induced by these parameters in the future physical activity and respiratory reservation of the patient, the importance of paying attention to the design of the field in these patients is emphasized. Radiotherapy is an essential component of breast cancer treatment and cannot be disregarded. Sometimes this beneficial treatment comprises several complications, including pneumonitis and pulmonary fibrosis. In addition to optimal radiotherapy treatment, the prevention of acute and chronic complications, such as pneumonitis and pulmonary fibrosis, is of importance for patients with breast cancer. Thus, the patients' normal life is not affected with these complications and their quality of life does not decrease.

### **Conflict of Interest**

None declared.

### **References**

1. Shieh Y, Tice JA. Medications for primary prevention of breast cancer. *JAMA*. 2020;324(3):291-2. doi:10.1001/jama.2020.9246.
2. Mohammadifard M, khazae Z, Mohammadifard M. The needs for screening of breast cancer, based on the latest guidelines. [In Persian] *J Birjand Univ Med Sci*. 2019;26(1):1-3 doi: 10.32592/JBirjandUnivMedSci.2019.26.1.100
3. Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, et al. Cancer screening in the

- United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening. *CA Cancer J Clin.* 2018;68(4):297-316. doi: 10.3322/caac.21446.
4. Wild CP. The global cancer burden: necessity is the mother of prevention. *Nat Rev Cancer.* 2019;19(3):123-4. doi: 10.1038/s41568-019-0110-3.
  5. Jeba J, Isiah R, Subhashini J, Backianathan S, Thangakunam B, Christopher DJ. Radiation pneumonitis after conventional radiotherapy for breast cancer: A prospective study. *J Clin Diagn Res.* 2015;9(7):XC01-XC05. doi: 10.7860/JCDR/2015/13969.6211.
  6. Aznar MC, Duane FK, Darby SC, Wang Z, Taylor CW. Exposure of the lungs in breast cancer radiotherapy: A systematic review of lung doses published 2010-2015. *Radiother Oncol.* 2018;126(1):148-54. doi: 10.1016/j.radonc.2017.11.022.
  7. AlSaeed EF, Balaraj FK, Tunio MA. Changes in pulmonary function tests in breast carcinoma patients treated with locoregional post-mastectomy radiotherapy: results of a pilot study. *Breast Cancer (Dove Med Press).* 2017;9:375-81. doi: 10.2147/BCTT.S114575.
  8. Palma DA, Senan S, Tsujino K, Barriger RB, Rengan R, Moreno M, et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. *Int J Radiat Oncol Biol Phys.* 2013;85(2):444-50. doi: 10.1016/j.ijrobp.2012.04.043.
  9. Lee TF, Chao PJ, Chang L, Ting HM, Huang YJ. Developing multivariable normal tissue complication probability model to predict the incidence of symptomatic radiation pneumonitis among breast cancer patients. *PLoS One.* 2015;10(7):e0131736. doi: 10.1371/journal.pone.0131736.
  10. Omarini C, Thanopoulou E, Johnston SR. Pneumonitis and pulmonary fibrosis associated with breast cancer treatments. *Breast Cancer Res Treat.* 2014;146(2):245-58. doi: 10.1007/s10549-014-3016-5.
  11. Giridhar P, Mallick S, Rath GK, Julka PK. Radiation induced lung injury: prediction, assessment and management. *Asian Pac J Cancer Prev.* 2015;16(7):2613-7. doi: 10.7314/apjcp.2015.16.7.2613.
  12. Delaney GP, Barton MB. Evidence-based estimates of the demand for radiotherapy. *Clin Oncol (R Coll Radiol).* 2015;27(2):70-6. doi: 10.1016/j.clon.2014.10.005.
  13. Vasiljevic D, Arnold C, Neuman D. Occurrence of pneumonitis following radiotherapy of breast cancer – A prospective study. *Strahlenther Onkol.* 2018; 194: 520-32. doi: 10.1007/s00066-017-1257-z.
  14. AlSaeed EF, Balaraj FK, Tunio MA. Changes in pulmonary function tests in breast carcinoma patients treated with locoregional post-mastectomy radiotherapy: results of a pilot study. *Breast Cancer (Dove Med Press).* 2017;9:375-81. doi: 10.2147/BCTT.S114575.
  15. Goldman U, Svane G, Anderson M, Wennberg B. Long-term functional and radiological pulmonary changes after radiation therapy for breast cancer, *Acta Oncologica.* 2014;53(10):1373-9. doi: 10.3109/0284186X.2014.934967.
  16. Abdemanafi SM, Tavakoli MB, Akhavan A, Abedi I. Evaluation of the lung volume changes in patients with breast cancer based on the received dose in the upper and lower lobes of the lung. *J Isfahan Med Sch.* 2019;37(514):60-5. doi: 10.1016/j.rpor.2019.09.005.
  17. Hernberg M, Virkkunen P, Maasilta P, Keyriläinen J, Blomqvist C, Bergh J, et al. Pulmonary toxicity after radiotherapy in primary breast cancer patients: results from

- a randomized chemotherapy study. *Int J Radiat Oncol Biol Phys.* 2002; 52: 128-36. doi: 10.1016/s0360-3016(01)01760-6.
18. Giridhar P, Mallick S, Rath G, Julka P. Radiation induced lung injury: Prediction, assessment and management. *Asian Pac J Cancer Prev.* 2015;16(7):2613-7. doi: 10.7314/apjcp.2015.16.7.2613.
19. Lind PA, Marks LB, Hardenbergh PH, Clough R, Fan M, Hollis D, et al. Technical factors associated with radiation pneumonitis after local +/- regional radiation therapy for breast cancer. *Int J Radiat Oncol Biol Phys.* 2002;52(1):137-43. doi: 10.1016/s0360-3016(01)01715-1.
20. Fragkandrea I, Kouloulis V, Mavridis P, Zettos A, Betsou S, Georgolopoulou P, et al. Radiation induced pneumonitis following whole breast radiotherapy treatment in early breast cancer patients treated with breast conserving surgery: a single institution study. *Hippokratia.* 2013;17(3):233-8.
21. Malekzade M, peykani S, amani O. Comparative study of quality of life in women survived with those suffered from breast cancer while under chemotherapy. [In Persian] *JHPM.* 2017;6(4) :8-14. doi: 10.21859/jhpm-07022.
22. Khoshbin A. Evaluation of pulmonary complications of tangential radiotherapy of breast cancers through pulmonary function tests and the effect of irradiated lung volume on it. *Med J Tabriz Uni Med Sciences.* 2010;33(1).25-28.
23. Vasiljevic D, Arnold C, Neuman D, Fink K, Popovscaia M, Kvitsaridze I, et al. Occurrence of pneumonitis following radiotherapy of breast cancer - A prospective study. *Strahlenther Onkol.* 2018;194(6):520-32. doi: 10.1007/s00066-017-1257-z.
24. Cho BC, Hurkmans CW, Damen EM, Zipp LJ, Mijnheer BJ. Intensity modulated versus non-intensity modulated radiotherapy in the treatment of the left breast and upper internal mammary lymph node chain: a comparative planning study. *Radiother Oncol.* 2002;62(2):127-36. doi: 10.1016/s0167-8140(01)00472-8.
25. Lund MB, Myhre KI, Melsom H, Johansen B. The effect on pulmonary function of tangential field technique in radiotherapy for carcinoma of the breast. *Br J Radiol.* 1991;64(762):520-3. doi: 10.1259/0007-1285-64-762-520.
26. Chang JH, Vines E, Bertsch H, Fraker DL, Czerniecki BJ, Rosato EF, et al. The impact of a multidisciplinary breast cancer center on recommendations for patient management: the University of Pennsylvania experience. *Cancer.* 2001;91(7):1231-7. doi: 10.1002/1097-0142(20010401)91:7<1231::aid-cncr1123>3.0.co;2-k.



Table 1. Demographics and clinical information of patients at baseline

<b>Variables</b>	<b>Level of variables</b>	<b>Patients with breast cancer (n=80)</b>
<b>Age, mean ± SD</b>		50.79±11.81
<b>Chemotherapy type (%)</b>	ACT	65(81.3)
	CMF	15(18.7)
<b>Surgery (%)</b>	BCT	39(48.8)
	MRM	41(51.2)
<b>Side (%)</b>	Right	48(60)
	Left	32(32)
<b>Chemotherapy time (%)</b>	Adjuvant	37(46.3)
	Neoadjuvant	43(53.8)
<b>HER2 (%)</b>	Negative	56 (70)
	Positive	24 (30)
<b>ER/PR (%)</b>	Negative	23(23.8)
	Positive	57(71.2)
<b>Stage</b>	Early	53(66.25)
	Advance	27 ( 33.75)

ACT: adriamycine, cyclophosphamide, paclitaxel; CMF: cyclophosphamide-methotroxate-5fu; BCT: breast conservating surgery; MRM: modified radical mastectomy; HER2: HER2 NEU receptor; ER: estrogen receptor PR: progesterone receptor; SD: Standard deviation

Table 2. Pulmonary function tests performed before and six months after radiotherapy

<b>Indexes</b>	<b>Baseline (Mean ± SD)</b>	<b>Six months later (Mean ± SD)</b>	<b>P-value</b>
<b>FEV1 (l/s)</b>	2.68 ± 0.30	2.48 ± 0.35	<0.0001
<b>FVC</b>	3.14 ± 0.32	2.91 ± 0.38	<0.0001
<b>FEV1/FVC</b>	85.12 ± 2.12	84.81 ± 2.10	<0.0001
<b>PaO2</b>	94.30 ± 1.71	94.15 ± 1.85	0.210

FEV1: Forced expiratory volume in one second; FVC: forced vital capacity; PaO2: pressure arterial o2; SD: Standard deviation

[Type here]

Table 3. The bivariate logistic regression models for developing clinical symptomatic fibrosis after radiotherapy

<b>Variables</b>	<b>Level of variables</b>	<b>Crude odds ratio (95% CI)</b>	<b>P-value</b>
<b>Age</b>		1.01 (0.95- 1.07)	0.650
<b>FEV1</b>		8.80 (0.29- 259.56)	0.203
<b>FVC</b>		10.74 (0.51 – 223.02)	0.121
<b>FEV1/FVC</b>		1.41 (0.56 – 3.57)	0.462
<b>Mean lung dose</b>		1.26 (1.03-1.53)	0.011
<b>Radiologic fibrosis</b>	Negative	1	--
	Positive	5.51 (1.10-27.42)	0.032
<b>Chemotherapy Type</b>	ACT (adriamycin- cyclophosphamide- paclitaxel)	1	--
	CMF (cyclophosphamide- methotroxate- 5fu)	1.04 (0.2-5.42)	0.904
<b>Surgery</b>	MRM	1	--
	BCT	1.30 (0.36 – 4.69)	0.671
<b>Chemotherapy time</b>	Neoadjuvant	1	--
	Adjuvant	1.47 (0.41 – 5.28)	0.557
<b>Side</b>	Left	1	--
	Right	3.46 (0.69 – 17.22)	0.121
<b>Her2</b>	Negative	1	--
	Positive	2.19 (0.59 – 8.03)	0.232
<b>ER/PR</b>	Negative	1	--
	Positive	0.66 (0.17 – 2.53)	0.550
<b>Stage</b>	Early	1	--
	Advanced	0.39 (0.07 – 1.95)	0.251

ACT: adriamycine, cyclophosphamide, paclitaxel; CMF: cyclophosphamide-methotroxate-5fu; CI: Confidence interval; BCT: breast conserving surgery; MRM: modified radical mastectomy; HER2: HER2 NEU receptor; ER: estrogen receptor; PR: progesterone receptor; FEV1: Forced expiratory volume in one second; FVC: forced vital capacity; PaO2: pressure arterial o2

[Type here]

Table 4. The bivariate and multivariate logistic regression models for developing radiologic fibrosis after radiotherapy

<b>Variables</b>	<b>Level of variables</b>	<b>Crude odds ratio (95% CI)</b>	<b>P-value</b>	<b>Adjusted odds ratio (95% CI)</b>	<b>P-value</b>
<b>Age</b>		1.06 (1.02 – 1.11)	0.002	1.12 (1.02 – 1.22)	0.133
<b>FEV1</b>		5.06 (2.57 – 9.95)	0.001	--	--
<b>FVC</b>		3.87 (2.23 – 6.72)	0.001	6.86 (2.50 – 18.78)	0.001
<b>FEV1/FVC</b>		1.07 (1.00 – 1.14)	0.041	1.19 (1.01 – 1.40)	0.032
<b>Mean lung dose</b>		1.22 (1.02 – 1.46)	0.023	--	--
<b>Clinical fibrosis</b>	Negative	1	--	--	--
	Positive	5.51 (1.10 – 27.42)	0.030	--	--
<b>Chemotherapy Type</b>	ACT	1	--	--	--
	CMF	2.33 (0.71 – 7.58)	0.150	--	--
<b>Surgery</b>	MRM	1	--	--	--
	BCT	0.60 (0.25 – 1.46)	0.260	--	--
<b>Chemotherapy time</b>	Neoadjuvant	1	--	--	--
	Adjuvant	1.35 (0.56 – 3.26)	0.500	--	--
<b>Side</b>	Left	1	--	--	--
	Right	1 (0.40 – 2.44)	1	--	--
<b>Her2</b>	Negative	1	--	--	--
	Positive	0.77 (0.30 – 2.05)	0.620	--	--
<b>ER/PR</b>	Negative	1	--	--	--
	Positive	3.14 (1.12 – 8.82)	0.033	--	--
<b>Stage</b>	Early	1	--	--	--
	Advanced	4.71 (1.69 – 13.31)	0.003	--	--

ACT: adriamycine, cyclophosphamide, paclitaxel; CMF: cyclophosphamide-methotrexate-5fu; BCT: breast conserving surgery; MRM: modified radical mastectomy; HER2: HER2 NEU receptor; ER: estrogen receptor; PR: progesterone receptor; FEV1: Forced expiratory volume in one second; FVC: forced vital capacity; PaO2: pressure arterial o2

[Type here]

Table 5. Univariate linear regression analysis of FEV1 changes

Variable	B	R <sup>2</sup>	P-value
Mean lung dose	0.17	0.03	0.131
Tamoxifen	0.06	0.004	0.582
Age	0.1	0.01	0.370




Figure 1. This figure shows pulmonary fibrosis scoring.

[Type here]